MLTX
Price:
$14.995
Market Cap:
$955.18M
MoonLake Immunotherapeutics, a clinical-stage biopharmaceutical company, engages in developing therapies. It is developing Sonelokimab, a novel investigational Nanobody therapy for the treatment of inflammation. The company is involved in conducting Phase II trials for hidradenitis suppurativa, psoriatic arthritis, ankylosing spondylitis, or radiographic axial spondyloarthritis. MoonLake Immunotherapeutics was founded in 2021 and is headquartered in Zug, Switzerland.
Industry
Biotechnology
IPO Date
2020-10-20
Stock Exchange
NASDAQ
Ticker
MLTX
According to MoonLake Immunotherapeutics’s latest financial reports and current stock price. The company's current ROE is -41.61%. This represents a change of 287.60% compared to the average of -10.74% of the last 4 quarters.
The mean historical ROE of MoonLake Immunotherapeutics over the last ten years is 58.96%. The current -41.61% ROE has changed -170.58% with respect to the historical average. Over the past ten years (40 quarters), MLTX's ROE was at its highest in in the December 2021 quarter at 19.08%. The ROE was at its lowest in in the March 2022 quarter at -65.10%.
Average
58.96%
Median
-7.26%
Minimum
-131.92%
Maximum
460.66%
Discovering the peaks and valleys of MoonLake Immunotherapeutics ROE, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 266.42%
Maximum Annual ROE = 460.66%
Minimum Annual Increase = -570527.39%
Minimum Annual ROE = -131.92%
| Year | ROE | Change |
|---|---|---|
| 2024 | -26.62% | 266.42% |
| 2023 | -7.26% | -94.49% |
| 2022 | -131.92% | -128.64% |
| 2021 | 460.66% | -570527.39% |
The current ROE of MoonLake Immunotherapeutics (MLTX) is greater than its 3-year, less than than its 5-year, and less than than its 10-year historical averages
3-year avg
-55.27%
5-year avg
58.96%
10-year avg
58.96%
MoonLake Immunotherapeutics’s ROE is greater than REGENXBIO Inc. (-78.29%), greater than MBX Biosciences, Inc. Common Stock (-29.28%), greater than Absci Corporation (-60.21%), greater than Verastem, Inc. (-9587.28%), greater than MeiraGTx Holdings plc (-1065.47%), greater than Erasca, Inc. (-31.19%), greater than Ventyx Biosciences, Inc. (-48.11%), greater than ArriVent BioPharma, Inc. Common Stock (-55.48%), greater than Olema Pharmaceuticals, Inc. (-41.51%), less than CytomX Therapeutics, Inc. (44.49%),
| Company | ROE | Market cap |
|---|---|---|
| -78.29% | $657.04M | |
| -29.28% | $1.03B | |
| -60.21% | $560.88M | |
| -9587.28% | $641.71M | |
| -1065.47% | $692.22M | |
| -31.19% | $905.04M | |
| -48.11% | $570.87M | |
| -55.48% | $1.01B | |
| -41.51% | $1.90B | |
| 44.49% | $691.03M |
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like MoonLake Immunotherapeutics using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
The easiest way to analyze a company like MoonLake Immunotherapeutics or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
What is the ROE?
How can you use the ROE?
What is MoonLake Immunotherapeutics's ROE?
How is the ROE calculated for MoonLake Immunotherapeutics (MLTX)?
What is the highest ROE for MoonLake Immunotherapeutics (MLTX)?
What is the 3-year average ROE for MoonLake Immunotherapeutics (MLTX)?
What is the 5-year average ROE for MoonLake Immunotherapeutics (MLTX)?
How does the current ROE for MoonLake Immunotherapeutics (MLTX) compare to its historical average?